2-Ethoxy-5-[(4-phenylpiperidino)sulfonyl]benzenecarboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Ethoxy-5-[(4-phenylpiperidino)sulfonyl]benzenecarboxylic acid
• 英文别名: 2-ethoxy-5-(4-phenylpiperidin-1-yl)sulfonylbenzoic acid
• 化学式: C₂₀H₂₃NO₅S
• 分子量: 389.5
• InChiKey: BRXFWBZYIASROL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  92.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME
  申请人：Del Mar Pharmaceuticals

  公开号：EP3217970A1

  公开（公告）日：2017-09-20
• USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20190015379A1

  公开（公告）日：2019-01-17

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
• US9487522B2
  申请人：——

  公开号：US9487522B2

  公开（公告）日：2016-11-08
• [EN] SSH-2 (SLINGSHOT-2) INHIBITORS AND METHODS FOR MAKING AND USING THEM<br/>[FR] INHIBITEURS DE SSH-2 (SLINGSHOT-2) ET PROCÉDÉS POUR LES PRÉPARER ET LES UTILISER
  申请人：UNIV CALIFORNIA

  公开号：WO2012129057A2

  公开（公告）日：2012-09-27

  In alternative embodiments, the invention provides compositions that inhibit the polypeptide SSH-2, or SlingSHot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting SSH-2, where in one embodiment compositions of the invention slow or inhibit F-actin depolymerization and severing. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit cell motility and/or internal remodeling. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit, or reverse, or ameliorate the progression of a cancer or a metastasis or other uncontrolled or unregulated cell growth, and/or Alzheimer's disease.
• [EN] DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME<br/>[FR] UTILISATION DE DIANHYDROGALACTITOL EN COMBINAISON AVEC DES RAYONS, POUR TRAITER LE CANCER DU POUMON NON À PETITES CELLULES ET LE GLIOBLASTOME MULTIFORME
  申请人：DEL MAR PHARMACEUTICALS

  公开号：WO2016077264A1

  公开（公告）日：2016-05-19

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.